Literature DB >> 1396896

Evidence for intact V1-vasopressin receptors in congenital nephrogenic diabetes insipidus.

N Knoers1, P M Janssens, J Goertz, L A Monnens.   

Abstract

The binding of tritium-labelled arginine vasopressin to human platelet vasopressin receptors was investigated in patients with congenital nephrogenic diabetes insipidus. Binding characteristics, that is receptor affinity and the maximum number of binding sites, were not significantly different from those found in normal control individuals. The findings confirm the concept of intact V1 receptors in congenital nephrogenic diabetes insipidus. The defect in nephrogenic diabetes insipidus apparently only affects the cyclic adenosine monophosphate dependent V2 receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396896     DOI: 10.1007/bf02113263

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  24 in total

1.  Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.

Authors:  N Knoers; E J Brommer; H Willems; B A van Oost; L A Monnens
Journal:  Nephron       Date:  1990       Impact factor: 2.847

2.  Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors.

Authors:  D A Jans; B A van Oost; H H Ropers; F Fahrenholz
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

3.  Characterization of human platelet vasopressin receptors.

Authors:  M Thibonnier; J M Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

4.  Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

Authors:  D G Bichet; M Razi; M Lonergan; M F Arthus; V Papukna; C Kortas; J N Barjon
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

5.  Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

Authors:  J D Cash; A M Gader; J da Costa
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

6.  Desmopressin and hypotension.

Authors:  E J Brommer; P van Brummelen; F H Derkx
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

7.  Homologous regulation of human platelet vasopressin receptors does not occur in vivo.

Authors:  D Vittet; J M Launay; C Chevillard
Journal:  Am J Physiol       Date:  1989-12

8.  Some properties of the human platelet vasopressin receptor.

Authors:  M E Thomas; A H Osmani; M C Scrutton
Journal:  Thromb Res       Date:  1983-12-15       Impact factor: 3.944

9.  Identification and characterization of vascular (V1) vasopressin receptors of an established smooth muscle cell line.

Authors:  F L Stassen; G Heckman; D Schmidt; N Aiyar; P Nambi; S T Crooke
Journal:  Mol Pharmacol       Date:  1987-03       Impact factor: 4.436

10.  V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation.

Authors:  J M Launay; D Vittet; M Vidaud; A Rondot; M N Mathieu; C Lalau-Keraly; B Cantau; C Chevillard
Journal:  Thromb Res       Date:  1987-02-15       Impact factor: 3.944

View more
  2 in total

Review 1.  Nephrogenic diabetes insipidus: identification of the genetic defect.

Authors:  N Knoers; A van den Ouweland; J Dreesen; M Verdijk; L A Monnens; B A van Oost
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

Review 2.  Nephrogenic diabetes insipidus: clinical symptoms, pathogenesis, genetics and treatment.

Authors:  N Knoers; L A Monnens
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.